HyperCVAD for VAD-resistant multiple myeloma

American Journal of Hematology

Volumn 52, Issue 2, 1996, Pages 77-81

  Dimopoulos, Meletios A ^a   Weber, Donna ^a   Kantarjian, Hagop ^a   Delasalle, Kay B ^a   Alexanian, Raymond ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

chemotherapy for myeloma; resistant multiple myeloma; VAD

Indexed keywords

ACICLOVIR; ALKYLATING AGENT; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0029971972     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199606)52:2<77::AID-AJH2>3.0.CO;2-2     Document Type: Article

References (17)

1. Jagannath S, Vesole D, Glenn L, et al: Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1666-1672, 1992.
2. Alexanian R, Dimopoulos M, Smith T, et al: Limited value of myeloablative therapy for late multiple myeloma. Blood 83:512-516, 1994.
3. Selby P, McElwain T, Nandi A, et al: Multiple myeloma treated with high-dose intravenous melphalan. Br J Haemat 66:55-62, 1987.
4. Barlogie B, Jagannath S, Dixon D, et al: High dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 76:677-680, 1990.
5. Dimopoulos M, Delasalle K, ChamplinR, Alexanian R: Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haemat 83:240-244, 1993.
6. Dimopoulos M, Hester J, Huh Y, Champlin R, Alexanian R: Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. Br J Haemat 87:730-734, 1994.
7. McLaughlin P, Alexanian R: Myeloma protein kinetics following chemotherapy. Blood 60:851-855, 1982.
8. Groopman J, Molina J, Scadden D: Hematopoietic growth factors. New Engl J Med 321:1449-1459, 1989.
9. Murphy S, Bowman W, Abromowitch M, et al: Results of treatment of advanced-stage Burkitt's lymphoma and B cell acute lymphoblastic leukemia with high-dose fractionaled cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol 4:1732-1739, 1986.
10. Kantarjian H, O'Brien S, Beran M, et al: Modified Burkitt regimen for adult acute lymphocytic leukemia: The hyperCVAD program. Blood 82(Suppl 1):329a, 1993 (abstr).
11. Lenhard R, Kalish L, Oken M, Ettinger D, Click J: Timed-sequential high-dose cyclophosphamide and vincristine in the treatment of multiple myeloma. Cancer 73:2113-2118, 1994.
12. Lenhard R, Daniels M, Oken M, et al: An aggressive high-dose cyclophosphamide and prednisone regimen for advanced myeloma. Leuk Lymph 13:485-489, 1994.
13. Dimopoulos M, Barlogie B, Smith T, Alexanian R: High serum lactate dehydrogenase level as a marker of drug resistance and short survival in multiple myeloma. Ann Intern Med 115:931-935, 1991.
14. Goldie J, Coldman A: A mathematic model for relating the drug sensitivity of tumors to their spontaneous remission rate. Cancer Treat Rep 63:1727-1733, 1979.
15. Drewinko B, Boyer H, Alexanian R, Barlogie B, Rubinow S. The growth fraction of human myeloma cells. Blood 57:333-338, 1981.
16. Takahashi T, Lim B, Jamal N, et al: Colony growth and self renewal of plasma cell precursors in multiple myeloma. J Clin Oncol 3:1613-1617, 1985.
17. Alexanian R, Dimopoulos M, Hester J, Delasalle K, Champlin R: Early myeloablative therapy for multiple myeloma. Blood 84:4278-4282, 1994.